Pharmaceutical company GM Pharma is expanding its export markets and plans to enter Germany. The company’s director, Gocha Gogilashvili, shared this during a presentation at the Parliamentary Price Commission.
Currently, GM Pharma’s medications are sold in eight countries, including Georgia, and the company aims to increase its export share.
“GM Pharma was founded in 2000. We import raw materials and manufacture medicines. Alongside Georgia, we are active in seven other countries: Kazakhstan, Kyrgyzstan, Uzbekistan, Tajikistan, Armenia, and Moldova. We also have registrations in Ukraine and Belarus. Our plans to enter these markets were delayed due to the ongoing war.
We have initiated registrations in Turkmenistan and Moldova. We are now pursuing registration in Germany - the process has already begun, with our application submitted to the German regulator. The German inspection will take place in October–November, and we plan to complete registration by February 2027.
In 2025, 43% of our production was sold domestically, while 57% was exported. Next year, we plan for 40% sales in Georgia and 60% abroad. With active entry into new markets starting at the end of this year, the export share will grow significantly by early 2027, as production cannot be sustained by domestic sales alone,” Gogilashvili stated.
